IP Library Granted Patent US 11,155,808
Granted Patent B2
US 11,155,808 · App. 17/208,519 · Granted Oct 26, 2021

HTP genomic engineering platform

Inventors: Zachariah Serber (Kenwood, CA); Erik Jedediah Dean (Lafayette, CA); Shawn Manchester (Oakland, CA); Katherine Gora (Oakland, CA); Michael Flashman (Eureka, CA); Erin Shellman (Seattle, WA); Aaron Kimball (San Francisco, CA); Shawn Szyjka (Martinez, CA); Barbara Frewen (Alameda, CA); Thomas Treynor (Berkeley, CA); Kenneth S. Bruno (Walnut Creek, CA)
Assignee: Zymergen Inc.
C12N15/1058B01L3/0275B01L3/5085C12N15/00C12N15/1075C12N15/1079C12N15/77C12N15/80G01N35/00871G01N35/10G16B5/00G16B20/00G16B40/00B01L2200/025B01L2200/0689B01L2200/16B01L2300/0627B01L2300/0672B01L2300/0681B01L2300/18B01L2300/1894
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,155,808
App. No.
17/208,519
Granted
Oct 26, 2021
Kind
B2
Abstract

The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.

Claims (20)

1. A computer-implemented high-throughput method of genomic engineering to identify target genes that have a beneficial effect on a phenotypic parameter of interest, comprising:

a) engineering the genome of a plurality of host cells to create a promoter swap host cell library, said library comprising a plurality of host cells with one or more promoters from a promoter ladder operably linked to a plurality of target genes present in the host cell to thereby create a plurality of promoter:gene target combinations,

wherein said promoter ladder comprises a plurality of promoters exhibiting different expression profiles in the host cell;

b) screening members of the plurality of host cells of the promoter swap host cell library by measuring a phenotypic performance metric;

e) creating a data set, comprising: input variables representing particular promoter:gene target combinations, and output variables representing phenotypic performance metric measurements associated with the promoter:gene target combinations; and

d) utilizing a machine learning model to analyze the data set and identify a target gene that has a beneficial effect on a phenotypic parameter of interest.

2. The method of claim 1 , wherein engineering the genome of the plurality of host cells to create a promoter swap host cell library of step a) is conducted with a gene editing technology selected from the group consisting of: ZFNs, TALENS, and CRISPR.

3. The method of claim 1 , wherein engineering the genome of the plurality of host cells to create a promoter swap host cell library of step a) is conducted with a CRISPR gene editing technology.

4. The method of claim 1 , comprising: manufacturing a host cell that comprises the target gene identified in step d).

5. The method of claim 1 , comprising: manufacturing a host cell that comprises a genetic alteration within coding sequence of a target gene identified in step d), said genetic alteration selected from the group consisting of a single nucleotide polymorphism, nucleotide sequence insertion, nucleotide sequence deletion, and nucleotide sequence replacement.

6. The method of claim 1 , comprising: manufacturing a host cell that comprises the target gene identified in step d), said target gene operably linked to one or more heterologous promoters.

7. The method of claim 1 , wherein the target gene identified in step d) is uncharacterized for improving phenotypic performance at the time the analysis is conducted.

8. The method of claim 1 , wherein a combination of at least two target genes are identified in step d), said combination of target genes being uncharacterized for improving phenotypic performance at the time the analysis is conducted.

9. The method of claim 1 , comprising: utilizing a machine learning model to predict expected phenotypic performance of a host cell that comprises a genetic alteration to at least two identified target genes from step d).

10. The method of claim 1 , wherein the machine learning model incorporates at least one of the following: linear regression, kernel ridge regression, logistic regression, neural networks, support vector machines (SVMs), decision trees, hidden Markov models, Bayesian networks, a Gram-Schmidt process, reinforcement-based learning, cluster-based learning, hierarchical clustering, genetic algorithms, or combinations thereof.

11. The method of claim 1 , wherein the machine learning model incorporates epistatic effects.

12. The method of claim 1 , wherein the machine learning model is supervised, semi-supervised, or unsupervised.

13. The method of claim 1 , wherein the phenotypic parameter of interest is selected from the group consisting of: volumetric productivity of a product of interest, specific productivity of a product of interest, yield of a product of interest, and titer of a product of interest.

14. The method of claim 1 , wherein the phenotypic parameter of interest is production of a product of interest.

15. The method of claim 1 , wherein the phenotypic parameter of interest is production of a product of interest, said product of interest selected from the group consisting of: a small molecule, enzyme, protein, peptide, amino acid, organic acid, synthetic compound, fuel, alcohol, primary extracellular metabolite, secondary extracellular metabolite, and intracellular component molecule.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2026
From: ZYMERGEN ACQUISITION SUB, INC.
To: GINKGO BIOWORKS, INC.
Reel/Frame 073519/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2025
From: ZYMERGEN INC.
To: ZYMERGEN ACQUISITION SUB, INC.
Reel/Frame 072825/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2021
From: SERBER, ZACHARIAH; DEAN, ERIK JEDEDIAH; MANCHESTER, SHAWN; GORA, KATHERINE; FLASHMAN, MICHAEL; SHELLMAN, ERIN; KIMBALL, AARON; SZYJKA, SHAWN; FREWEN, BARBARA; TREYNOR, THOMAS; BRUNO, KENNETH S.
To: ZYMERGEN INC.
Reel/Frame 056639/0731 →
Continuity (10)
Continuation 17071691 · Oct 15, 2020
Continuation 16838409 · Apr 2, 2020
Continuation 16458376 · Jul 1, 2019
Continuation 15923527 · Mar 16, 2018
Continuation 15396230 · Dec 30, 2016
Continuation PCTUS2016065465 · Dec 7, 2016
Continuation In Part 15140296 · Apr 27, 2016
Provisional Application 62368786 · Jul 29, 2016
Provisional Application 62264232 · Dec 7, 2015
Related Publication 20210222156A1 · Jul 22, 2021